Navigation Links
20 Swiss Biotech Firms and Organizations will Populate the Swiss Pavilion at BIO 2013 International Convention
Date:4/16/2013

NEW YORK, April 16, 2013 /PRNewswire/ -- Twenty Swiss-based biotech industry companies and organizations are highlighting their expertise at the Swiss Pavilion (Booth 5454, Hall A) during the BIO International Convention April 22-25 in Chicago, reports Daniel Bangser, Director North America for Switzerland Trade & Investment Promotion. Some 150 additional representatives of biotech firms in Switzerland are expected to attend.

Presentations include:

Advances and Emerging Trends in the Swiss Biotech Market, with Nic Alexakis , CEO of the Swiss Biotech Association, and Juergen Regenold , CEO of regulanet (Monday Apr 22, 10:00 AM - 10:45 AM)

Summary of the Swiss Biotech Report 2013

For 2012, net sales in the Swiss biotech industry remained stable despite the European debt crisis. Biotech activities of Swiss companies remained high as revealed by the number of products in the clinical pipeline.

  • Net sales amounted to a total of CHF 4,642 billion, about 1% less than the previous year.
  • Capital investments in Swiss biotech companies amounted to approximately CHF 260 million. Though significantly lower than 2011, the overall picture looks similar when debt financing is removed from the analysis.
  • The number of biotech firms increased slightly from the previous year to 250 developers and suppliers. The number of employees totals over 13,700.

"A well-functioning transfer of knowledge and technology combined with a high degree of innovation are key components of Switzerland's prosperity," Mr. Bangser said.  "Swiss biotech companies play an important role in this process.  Success is largely due to the excellent cooperation between universities, research networks, government institutions and the many small and large biotech companies. The Swiss Biotech Association will continue to support and promote this cooperation in the coming years with a broad range of measures."

Download the Swiss Biotech Report 2013 (3.5 MB)

www.locationswitzerland.com  


'/>"/>
SOURCE Switzerland Trade & Investment Promotion
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. VBI’s Dr. Szczepan Baran is an Invited Speaker at the Swiss Laboratory Animal (SGV) National Meeting
2. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
3. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
4. Fytofontana Cosmeceuticals: The Swiss Secret For Incredibly Young And Beautiful Skin
5. Heptares to Present at Upcoming Scientific and Biotech Industry Conferences
6. Global Biotechnology Industry Market Research Report Now Available from IBISWorld
7. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
8. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
9. Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase
10. Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market
11. San Diego State University Hosts Open House for Life Science Immersion Biotechnology Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
Breaking Biology Technology:
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
Breaking Biology News(10 mins):